Language

Pediatric Endocrinology

Pediatric Endocrinology - Research

Gad B. Kletter, MD is a board-certified endocrinologist specializing in the diagnosis and treatment of the endocrine system and hormone disorders in infants, children and adolescents. His clinical areas of interest are in early and delayed onset puberty-related disorders. He treats adrenal disorders, constitutional growth delay, thyroid disorders and short stature.

With over thirty years of experience in pediatric endocrinology, Dr. Kletter comes with national and international respect from his peers and is a leading researcher in his field.  Dr. Kletter conducts various patient research studies to advance treatment and is published in numerous professional articles.

Other areas of focus Dr. Kletter provides include:

  • Precocious puberty
  • Calcium and Phosphorous disorders
  • Hypoglycemia and Hyperlipidemia
  • Pituitary disorders

If you are interested in hearing more or would like to schedule time to discuss research opportunities with him, please call to make an appointment at one of his locations:

Mary Bridge Pediatric Specialty Clinic - Covington:

Phone: 253-403-7296

Mary Bridge Children's Health Center - Tacoma

Phone:  253-403-7296

Pediatric Endocrinology Studies Accepting Patients

Pediatrics - PCC Orphan Reach

Study Number: TOL2581—An open-label, single arm, multicenter study on the efficacy, safety and pharmacokinetics of Leuprolide Acetate 45 mg for injectable suspension controlled release in subjects with central precocious puberty (CPP).

Study Info

Principal Investigator(s): Gadi Kletter, MD

Study Coordinator: Katy Garrison, 253-403-2699

Pediatrics - MK-0431-083 T2DM

Study Number: MK-0431-083—A Phase III, multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Sitagliptin in pediatric patients with Type 2 diabetes mellitus with inadequate glycemic control.

Study Info

Principal Investigator(s): Gadi Kletter, MD

Study Coordinator: Katy Garrison, 253-403-2699

Pediatrics - MK-0431A-289 T2DM

Study Number: MK-0431A-289—A Phase III multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of MK-0431A XR (a fixed-dose combination tablet of Sitagliptin and extended-release Metformin) in pediatric patients with Type 2 diabetes mellitus with inadequate glycemic control on
Metformin therapy (alone or in combination with insulin).

Study Info

Principal Investigator(s): Gadi Kletter, MD

Study Coordinator: Katy Garrison, 253-403-2699

Pediatrics - AWARD T2DM

Study Number: H9X-MC-GBGC – A randomized, double-blind study with an open-label extension comparing the effect of once-weekly Dulaglutide with placebo in pediatric patients with Type II Diabetes Mellitus.

Study Info

Principal Investigator: Gadi Kletter, MD

Study Coordinator: Katy Garrison, [email protected], 253-403-2699

Pediatrics - T1GER

Study Number: CNTO148DML2001—A study of SIMPONI to arrest beta-cell loss in Type I diabetes (T1GER). 

Study Info

Principal InvestigatorGadi Kletter, MD 

Study Coordinator: Katy Garrison, [email protected], 253-403-2699

Pediatrics - 13VR3 Vista

Study Number: 13VR3—An Open-Label, Long-Term Safety Study of A Longacting Human Growth Hormone Somavaratan (VRS-317) in Children with Growth Hormone Deficiency; The VISTA Study: Versartis Long-Term Safety Study of Somavaratan.

Study Info

Principal InvestigatorGadi Kletter, MD 

Study Coordinator: Katy Garrison, [email protected], 253-403-2699

Pediatrics - NN8640-4172 GHD

Study Number: NN8640-4172—A randomized, multinational, active-controlled, open-labelled, dose finding, double-blinded, parallel group trial investigating efficacy and safety of once-weekly NNC0195-0092 treatment compared to daily growth hormone treatment (Norditropin® FlexPro®) in growth hormone treatment naïve pre-pubertal children with growth hormone deficiency

Study Info

Principal InvestigatorGadi Kletter, MD 

Study Coordinator: Katy Garrison, [email protected], 253-403-2699

Pediatrics - ASCENDIS hGH

Study NumberTransCon hGH CT-301—A multicenter, Phase III, randomized, open-label, active controlled, parallel-group trial investigating the safety, tolerability, and efficacy of TransCon hGH administered once a week versus standard daily hGH replacement therapy over 52 weeks prepubertal children with growth hormone deficiency (GHD).

Study Info

Principal InvestigatorGadi Kletter, MD 

Study Coordinator: Katy Garrison, [email protected], 253-403-2699